BioTime Awarded a $4.7 Million Research Grant from the California Institute for Regenerative Medicine

Published: Apr 30, 2009

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc., (OTCBB:BTIM) announced today that the California Institute for Regenerative Medicine (CIRM) has approved a grant to the Company of $4.7 million to fund research related to its ACTCellerateâ„¢ embryonic stem cell technology. The overall objective of this grant is to generate tools useful in applying ACTCellerateâ„¢ technology to the manufacture of patient-specific therapeutic products.

Back to news